Tagraxofusp

Generic name: Tagraxofusp
Brand names: Elzonris
Dosage form: intravenous solution (1000 mcg/mL)
Drug class: Miscellaneous antineoplastics

Usage of Tagraxofusp

Tagraxofusp is used to treat blastic plasmacytoid dendritic cell neoplasm, a rare blood and/or bone marrow cancer.

tagraxofusp is for use in adults and children at least 2 years old.

Tagraxofusp may also be used for purposes not listed in this medication guide.

Tagraxofusp side effects

Get emergency medical help if you have signs of an allergic Reaction: hives, rash, itching; mouth sores; sudden warmth or tingly feeling; difficult breathing; swelling of your face, lips, tongue, or throat.

Capillary leak syndrome is a serious side effect of tagraxofusp. Call your doctor right away if you have a stuffy or runny nose followed by:

tiredness or dizziness;

thirst;

decreased urination;

trouble breathing; and

sudden swelling or weight gain.

Common side effects of tagraxofusp may include:

capillary leak syndrome;

nausea;

tiredness;

swelling in your hands or feet;

fever; or

weight gain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Tagraxofusp

You may need to have a negative pregnancy test 1 week before starting this treatment.

Tagraxofusp may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using tagraxofusp and for at least 1 week after your last dose.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

Relate drugs

How to use Tagraxofusp

Usual Adult Dose for Malignant Disease:

12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-Day cycle until disease progression or uNACceptable toxicityComments:-Premedicate patients with an H1-Histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., Ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.-The dosing period may be extended for dose delays up to Day 10 of the cycle. Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Usual Pediatric Dose for Malignant Disease:

2 years and older:12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-day cycle until disease progression or unacceptable toxicityComments:-Premedicate patients with an H1-histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.-The dosing period may be extended for dose delays up to Day 10 of the cycle. Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients 2 years and older

Warnings

Call your doctor right away if you have signs of a serious side effect called capillary leak syndrome: stuffy or runny nose followed by tiredness or dizziness, thirst, decreased urination, trouble breathing, and sudden swelling or weight gain.

What other drugs will affect Tagraxofusp

Other drugs may affect tagraxofusp, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.